Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar

The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin’s lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-age...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachpekidis, Christos, Jackson, David B., Soldatos, Theodoros G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958320/
https://www.ncbi.nlm.nih.gov/pubmed/31546999
http://dx.doi.org/10.3390/ph12040141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958320/
https://www.ncbi.nlm.nih.gov/pubmed/31546999
http://dx.doi.org/10.3390/ph12040141

Ejemplares similares